LB PHARMACEUTICALS INC (LBRX) — insider trading
Health Care · NASDAQ
LB PHARMACEUTICALS INC (LBRX) has 14 reported SEC Form 4 insider transactions in our data, including 3 open-market purchases among the most recent 14 (latest 2026-10-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | Kozauer Susan Gani | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 200,000 | — | $0 | Form 4 |
| 2026-10-09 | Miller Joseph M | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 200,000 | — | $0 | Form 4 |
| 2026-07-30 | Deep Track Biotechnology Master Fund, Ltd.; Deep Track Capital, LP; KROIN DAVID | 10% owner | Open-market purchase (derivative) | 286,205 | $34.94 | $10.00M | Form 4 |
| 2026-06-03 | Garland J. Scott | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-03 | Kane William P Jr | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-03 | Hemrajani Rekha | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-03 | Lenz Robert A. | Director | Grant / award / vesting (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-06-03 | Luse Rebecca | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-03 | Nussbaum Ran | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-03 | RUFFOLO ROBERT R | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-03-06 | Lenz Robert A. | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-02-06 | Deep Track Biotechnology Master Fund, Ltd.; Deep Track Special Opportunities Fund, LP; Deep Track Capital, LP; KROIN DAVID | 10% owner | Open-market purchase (derivative) | 93,925 | $21.17 | $1.99M | Form 4 |
| 2026-02-06 | Deep Track Biotechnology Master Fund, Ltd.; Deep Track Special Opportunities Fund, LP; Deep Track Capital, LP; KROIN DAVID | 10% owner | Open-market purchase (derivative) | 378,444 | $21.17 | $8.01M | Form 4 |
| 2025-12-10 | Pai Panandiker Kaya Kamlesh | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 195,000 | — | $0 | Form 4 |
Ask the chat about LBRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: LB PHARMACEUTICALS INC (LBRX).
Last updated 2026-10-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.